Resources

A Whitepaper That Looks at How GenAI-Powered Automation Is Helping Teams Prepare for the Future of Regulatory Submissions

Claret Capital Partners has invested €10M in Yseop to support global expansion and accelerate development of its Generative AI platform. Yseop Copilot helps leading pharma companies like Eli Lilly and Novartis create compliant regulatory documentation faster and with greater consistency.

Yseop’s first CMC-focused offering automates the Quality Overall Summary (Module 2.3), a central component of regulatory submissions that pulls structured insights from Module 3.2.

With 27,000+ reports generated per month, Yseop solidifies its leadership in regulatory automation ahead of its DIA 2025 showcase.

Listen to the next episode of AI Uncovered with Karla Childers.

The FDA has begun using generative AI to review drug submissions, signaling a major shift in regulatory review. Learn how this impacts pharma teams and what it takes to make your content AI-ready.

Listen to the thirteenth episode of AI Uncovered with Emmanuel Walckenaer

Listen to the twelfth episode of AI Uncovered with Emmanuel Walckenaer

With Generative AI on AWS, Yseop is streamlining pharmaceutical processes to improve patient outcomes worldwide. Discover our story behind Europe’s breakthrough innovations with AWS Pioneers Project.